Full text
Earnings transcript
Read the complete earnings call transcript.
SLP
Simulations Plus, Inc.
$18.5
0
(0%)
| Exchange: | NASDAQ |
| Market Cap: | 374.16M |
| Shares Outstanding: | 2.222M |
Delayed data
About The Company
| Sector: | TechnologyView sector performance | |||||
| Industry: | Software – ApplicationView industry performance | |||||
| CEO: | Shawn O’Connor | |||||
| Full Time Employees: | 213 | |||||
| Address: |
| |||||
| Website: | https://www.simulations-plus.com |
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Click to read more…
Revenue Segmentation
SLP full analysis
YouTube Video Transcript: Comprehensive Stock Analysis of Simulations Plus, Inc. (SLP) Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive stock analysis of Simulations Plus, Inc., ticker symbol SLP. If you’re into healthcare tech or looking for niche players in the drug development space, this video is for you. We’re going to break down everything from their business model to financials, valuation, and even intrinsic value. So, grab a coffee, hit that like button if…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 59,577 | 70,013 | 79,179 |
| Gross Profit | 47,947 | 43,151 | 46,221 |
| EBITDA | 13,065 | 18,076 | 14,703 |
| Operating Income | 8,725 | 6,131 | -70,729 |
| Net Income | 9,961 | 9,954 | -64,718 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 186,101 | 196,639 | 131,936 |
| Total Liabilities | 16,072 | 14,208 | 7,135 |
| Total Stockholders Equity | 170,029 | 182,431 | 124,801 |
| Total Debt | 1,197 | 1,006 | 616 |
| Cash and Cash Equivalents | 57,523 | 10,311 | 30,853 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 21,856 | 13,320 | 18,126 |
| Capital Expenditure | -4,273 | -566 | -713 |
| Free Cash Flow | 17,583 | 12,754 | 17,413 |
| Net Income | 9,961 | 9,954 | -64,718 |
| Net Change in Cash | 5,956 | -47,212 | 20,542 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 116,592.032 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 117,477.767 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 117,100 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 42,505.163 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 42,864.132 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 42,711.090 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 31,180.672 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 31,489.022 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 31,357.561 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 54,794.982 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 55,211.252 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 55,033.712 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 1.560 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 1.570 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 1.550 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 1 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Growth: Simulations Plus reported a 13% increase in revenue for Q4 FY2025, as highlighted in the earnings call transcript, reflecting strong top-line performance and operational efficiency compared to prior periods.
- Innovative Product Pipeline: The company emphasized upcoming product enhancements during the earnings call, indicating a focus on innovation that could sustain competitive advantage within the software and simulation industry.
- Positive Financial Metrics: Key metrics such as gross profit margin and net profit margin (specific figures to be derived from Key Metrics TTM data) suggest profitability, while a healthy free cash flow yield (from Key Metrics TTM) supports financial stability for reinvestment or debt management.
- Strong Market Positioning: As noted in the earnings call, Simulations Plus is well-positioned to capitalize on improved market conditions, supported by its established presence in the industry (reflected in sector and industry performance data).
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates SLP intrinsic value between $22.44 – $25.71 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about SLP valuation
Is Simulations Plus, Inc. (SLP) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Simulations Plus, Inc. (SLP) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SLP a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SLP trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SLP’s P/E ratio?
You can see SLP’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SLP?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SLP a good long-term investment?
Whether SLP fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SLP
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0
Trading Metrics:
| Open: | 18.5 | Previous Close: | 18.5 | |
| Day Low: | 18.5 | Day High: | 18.5 | |
| Year Low: | 11.09 | Year High: | 21.01 | |
| Price Avg 50: | 18.39 | Price Avg 200: | 16.35 | |
| Volume: | 0 | Average Volume: | 364244 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
